Načítá se...
Development of Liposomal Ciprofloxacin to Treat Lung Infections
Except for management of Pseudomonas aeruginosa (PA) in cystic fibrosis, there are no approved inhaled antibiotic treatments for any other diseases or for infections from other pathogenic microorganisms such as tuberculosis, non-tuberculous mycobacteria, fungal infections or potential inhaled biowar...
Uloženo v:
| Vydáno v: | Pharmaceutics |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4810082/ https://ncbi.nlm.nih.gov/pubmed/26938551 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics8010006 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|